Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C30H35NO3
CAS Number:
Molecular Weight:
457.60
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥95% (HPLC)
Form:
film or powder (or oil)
Product Name
Ormeloxifene, ≥95% (HPLC)
InChI key
XZEUAXYWNKYKPL-WDYNHAJCSA-N
SMILES string
CC([C@@H](C1=CC=CC=C1)[C@@H]2C3=CC=C(OCCN4CCCC4)C=C3)(C)OC5=C2C=CC(OC)=C5
InChI
1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
assay
≥95% (HPLC)
form
film or powder (or oil)
color
colorless to yellow-white
storage temp.
2-8°C
Related Categories
Biochem/physiol Actions
Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.
non-steroidal selective estrogen receptor modulator (SERM)
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
William R Surin et al.
Journal of basic and clinical physiology and pharmacology, 1-8 (2014-01-29)
Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is well established in clinical settings, and thrombin has been found to induce angiogenesis at cancer sites. This establishes a link between cardiovascular diseases
Bilal Bin Hafeez et al.
Molecular cancer therapeutics, 16(10), 2267-2280 (2017-06-16)
Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism
Geetika Kharkwal et al.
Journal of molecular endocrinology, 48(3), 261-270 (2012-04-12)
Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone resorption in rats. However, the precise mechanism underlying the bone-preserving action of Orm remains unclear. In this study, we evaluated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service